Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B

Yuanmei CHE; Ai LI; Liang WANG; Lunli ZHANG; Xiaopeng LI

doi:10.3969/j.issn.1001-5256.2023.06.010

Volume 39 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(6): 1313-1317

PDF( 1738 KB)

Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.06.010

Yuanmei CHE^{1, 2},
Ai LI^{1, 3},
Liang WANG¹,
Lunli ZHANG¹,
Xiaopeng LI^{1
,
,
,}

1.
Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
2.
Department of Infectious Diseases, Jiangxi Provincial People's Hospital, Nanchang 330006, China
3.
Department of Blood Transfusion, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, China

Research funding:

Science and Technology Plan Project of Jiangxi Provincial (20161BCD40015);

Science and Technology Plan Project of Jiangxi Provincial (20212BAG70022);

Teaching Reform Project of Nanchang University (NCUJGLX-2020-166-162)

More Information

Corresponding author: LI Xiaopeng, lixiaopeng823@163.com (ORCID: 0000-0003-3644-4976)
Received Date: 2022-09-30
Accepted Date: 2023-02-03
Published Date: 2023-06-20

Abstract

Abstract

Objective To investigate the possible influence of long-term antiviral therapy with entecavir on renal function in patients with chronic hepatitis B (CHB) and the sensitive indicators for early identification of renal injury. Methods A cross-sectional real-world study was conducted for the clinical data of 125 CHB patients treated with entecavir for more than 1 year (treatment group) and 44 patients with chronic HBV infection who did not receive antiviral therapy (control group), including the changes in serum creatinine (SCr), estimated glomerular filtration rate (eGFR), and the levels of urinary α1 microglobulin (α1-MG), β2 microglobulin (β2-MG), and N-acetyl-β-D-glucosaminidase (NAG). The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The independent-samples t test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Logistic regression analysis was used to investigate independent influencing factors for abnormal urinary α1-MG, β2-MG, and NAG in the treatment group. Results There were no significant differences in SCr and eGFR between the treatment group and the control group (t=0.999 and -1.259, P > 0.05), and both indices were within the normal range in these two groups. The treatment group had significantly higher abnormal rates of urinary α1-MG and β2-MG than the control group (47.2%/42.4% vs 13.6%/13.6%, χ²=15.693 and 12.567, both P < 0.001), and compared with the control group, the treatment group had a significantly higher proportion of patients with α1-MG or β2-MG > 2×upper limit of normal (18.4%/21.6% vs 2.3%/4.5%, both P < 0.05); however, there were no significant differences between the treatment group and the control group in the abnormal rate of urinary NAG (8.0% vs 6.8%, P > 0.05) and the proportion of patients with urinary NAG > 2×upper limit of normal (8.8% vs 6.8%, P > 0.05). Compared with the control group, the treatment group had a significantly higher proportion of patients with abnormalities in two or more indicators for renal tubular injury (33.6% vs 11.4%, χ²=8.519, P < 0.05), while there was no significant difference between the two groups in the proportion of patients with abnormalities in one indicator (16.0% vs 11.4%, P > 0.05). Conclusion Long-term treatment of CHB with entecavir may be associated with the risk of renal tubular dysfunction, and abnormalities in more than two indicators for renal injury may help to identify renal tubular dysfunction in patients, so as to adjust related treatment in time.
- Hepatitis B, Chronic,
- Entecavir,
- Acute Kidney Injury

FullText(HTML)

References(13)

References

[1]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[2]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[3]	MAK LY, HOANG J, JUN DW, et al. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study[J]. Hepatol Int, 2022, 16(1): 48-58. DOI: 10.1007/s12072-021-10271-x.
[4]	HU GF, LI XP, WU ZP, et al. Clinical features of acute on chronic liver failure induced by withdrawal of nucleos(t)ide analogues[J]. J Clin Hepatol, 2017, 33(7): 1320-1323. DOI: 10.3969/j.issn.1001-5256.2017.07.023. 胡高飞, 李小鹏, 吴振平, 等. 停用核苷和核苷酸类药物抗HBV后诱发慢加急性肝衰竭的临床特征[J]. 临床肝胆病杂志, 2017, 33(7): 1320-1323. DOI: 10.3969/j.issn.1001-5256.2017.07.023.
[5]	LAMPERTICO P, BUTI M, RAMJI A, et al. A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results[J]. J Hepatol, 2020, 73: S67-S68. DOI: 10.1016/S0168-8278(20)30670-X.
[6]	JUNG CY, KIM HW, AHN SH, et al. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B[J]. Liver Int, 2022, 42(5): 1017-1026. DOI: 10.1111/liv.15208.
[7]	WONG GL, CHAN HL, TSE YK, et al. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment[J]. Aliment Pharmacol Ther, 2018, 48(9): 984-992. DOI: 10.1111/apt.14945.
[8]	MTISI TJ, NDHLOVU CE, MAPONGA CC, et al. Tenofovir-associated kidney disease in Africans: a systematic review[J]. AIDS Res Ther, 2019, 16(1): 12. DOI: 10.1186/s12981-019-0227-1.
[9]	ROBINSON DM, SCOTT LJ, PLOSKER GL. Entecavir: a review of its use in chronic hepatitis B[J]. Drugs, 2006, 66(12): 1605-1622; discussion 1623-1624. DOI: 10.2165/00003495-200666120-00009.
[10]	RIVKIN A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B[J]. Drugs Today (Barc), 2007, 43(4): 201-220. DOI: 10.1358/dot.2007.43.4.1037479.
[11]	MATTHEWS SJ. Entecavir for the treatment of chronic hepatitis B virus infection[J]. Clin Ther, 2006, 28(2): 184-203. DOI: 10.1016/j.clinthera.2006.02.012.
[12]	LEE W, KIM RB. Transporters and renal drug elimination[J]. Annu Rev Pharmacol Toxicol, 2004, 44: 137-166. DOI: 10.1146/annurev.pharmtox.44.101802.121856.
[13]	YANG X, MA Z, ZHOU S, et al. Multiple drug transporters are involved in renal secretion of entecavir[J]. Antimicrob Agents Chemother, 2016, 60(10): 6260-6270. DOI: 10.1128/AAC.00986-16.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (602) PDF downloads(86)

Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.06.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.06.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content